Evidence map›Paper›PMID 40217076›Full record

ReviewNature medicine2025

Clinical translation of microbiome research.

Jack A Gilbert, Meghan B Azad, Fredrik Bäckhed, Martin J Blaser, Mariana Byndloss, Charles Y Chiu, Hiutung Chu, Lara R Dugas, Eran Elinav, Sean M Gibbons and 12 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Principles for Rigorous Design and Application of Synthetic Microbial Communities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Dissecting the Ecological Structure of Health and Disease in the Global Gut Microbiome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Gut microbiota in health and disease.Molecular biomedicine · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jack A GilbertDepartment of Pediatrics, University of California San Diego, La Jolla, CA, USA. gilbertjack@gmail.com.ORCID http://orcid.org/0000-0001-7920-7001
Meghan B AzadDepartment of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.ORCID http://orcid.org/0000-0002-5942-4444
Fredrik BäckhedWallenberg Laboratory and Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Martin J BlaserCIFAR Humans & the Microbiome Program, CIFAR, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-2447-2443
Mariana ByndlossDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Charles Y ChiuDepartment of Laboratory Medicine, University of California, San Fransisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-2915-2094
Hiutung ChuCenter for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA.
Lara R DugasPublic Health Sciences, Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Maywood, IL, USA.
Eran ElinavDepartment of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0002-5775-2110
Sean M GibbonsInstitute for Systems Biology, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-8724-7916
Katharine E GilbertCenter for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA.
Matthew R HennSeres Therapeutics, Inc., Cambridge, MA, USA.
Suzanne L IshaqSchool of Food and Agriculture, University of Maine, Orono, ME, USA.ORCID http://orcid.org/0000-0002-2615-8055
Ruth E LeyDepartment of Microbiome Science, Max Planck Institute for Biology, Tübingen, Germany.ORCID http://orcid.org/0000-0002-9087-1672
Susan V LynchBenioff Center for Microbiome Medicine, Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5695-7336
Eran SegalDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0002-6859-1164
Tim D SpectorDepartment of Twin Research and Genetic Epidemiology, King's College London, London, UK.
Philip StrandwitzHolobiome, Boston, MA, USA.
Jotham SuezW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-3836-972X
Carolina TropiniCIFAR Humans & the Microbiome Program, CIFAR, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-7542-1577
Katrine WhitesonDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, USA.
Rob KnightDepartment of Pediatrics, University of California San Diego, La Jolla, CA, USA.

Funding

Obesogenic diet-induced intestinal epithelium repair responses link dysbiosis and cardiovascular diseaseR01DK131104 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Mariana Xavier Byndloss · 2022 to 2026
$2.4M
NIDDK NIH HHS R01 DK131104
6 · The paper itself

Abstract

The landscape of clinical microbiome research has dramatically evolved over the past decade. By leveraging in vivo and in vitro experimentation, multiomic approaches and computational biology, we have uncovered mechanisms of action and microbial metrics of association and identified effective ways to modify the microbiome in many diseases and treatment modalities. This Review explores recent advances in the clinical application of microbiome research over the past 5 years, while acknowledging existing barriers and highlighting opportunities. We focus on the translation of microbiome research into clinical practice, spearheaded by Food and Drug Administration (FDA)-approved microbiome therapies for recurrent Clostridioides difficile infections and the emerging fields of microbiome-based diagnostics and therapeutics. We highlight key examples of studies demonstrating how microbiome mechanisms, metrics and modifiers can advance clinical practice. We also discuss forward-looking perspectives on key challenges and opportunities toward integrating microbiome data into routine clinical practice, precision medicine and personalized healthcare and nutrition.

Indexed as

MicrobiotaPrecision MedicineTranslational Research, BiomedicalClostridioides difficileClostridium InfectionsHumans

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.